Johnson & Johnson ANZ

Johnson & Johnson ANZ At Johnson & Johnson, we believe health is everything. Follow us to see how we're connecting the best of Health&Care.

At Johnson & Johnson Innovative Medicine, we address some of the most complex diseases of our time and unlock the potential medicines of tomorrow. Our diverse portfolio spans multiple therapeutic areas - Cardiovascular, Metabolism & Retina, Immunology, Infectious Diseases, Neuroscience, Oncology, and Pulmonary Hypertension.
​
Learn more about Johnson & Johnson Innovative Medicine Australia at www.janssen.com.au and Johnson & Johnson Innovative Medicine New Zealand at www.janssen.com/newzealand/

This page is monitored Monday-Friday between standard business operating hours. Read our Community Guidelines here:https://www.janssen.com/australia/sites/www_janssen_com_australia/files/janssen_anz_social_media_community_guidelines.pdf

Janssen-Cilag Pty Ltd is a Johnson & Johnson company.

Today marks . Nearly 180,000 Australians live with inflammatory bowel disease (IBD) – a lifelong, invisible condition t...
19/05/2025

Today marks . Nearly 180,000 Australians live with inflammatory bowel disease (IBD) – a lifelong, invisible condition that many are too ashamed to talk about. Many patients experience significant delays in getting a proper diagnosis, highlighting the urgent need for increased awareness.

J&J is proud to partner with Crohn's & Colitis Australia to help bring attention to IBD symptoms and support those living with the condition. Together, we aim to and encourage open conversations about IBD.

: Australians with an aggressive form of lung cancer now have affordable access to a new targeted medicine.The bispecif...
02/05/2025

: Australians with an aggressive form of lung cancer now have affordable access to a new targeted medicine.

The bispecific antibody RYBREVANT® (amivantamab) is now available through the Pharmaceutical Benefits Scheme (PBS) for Australians with locally advanced or metastatic non-small cell lung cancer (NSCLC) caused by changes (Exon-20 insertion alterations) in the epidermal growth factor receptor (EGFR) gene.

This form of lung cancer is most common in non-smokers and patients who are younger than those with other types of lung cancer.

Until now, these patients have had limited treatment options available via the PBS.

We’d like to thank all Australians who advocated for access to this new treatment option.

As with all medicines, RYBREVANT may be associated with side effects. The most common side effects include skin rash, paronychia (infection of the skin around a fingernail or toenail), stomatitis (inflammation of the lining of the mouth), infusion-related reaction and fatigue. Please refer to the Rybrevant Consumer Medicine Information for further information:https://innovativemedicine.jnj.com/australia/download/rybrevant-cmi.pdf

: The first once-daily single tablet combination therapy for patients with pulmonary arterial hypertension (PAH) has be...
02/05/2025

: The first once-daily single tablet combination therapy for patients with pulmonary arterial hypertension (PAH) has been added to the Pharmaceutical Benefits Scheme (PBS). PBS listing of Opsynvi® (macitentan/ tadalafil) will allow adult patients with PAH who are on stable doses of macitentan 10mg and tadalafil 40mg (20mg x 2) as separate tablets to substitute treatment with this new therapy.

PAH is caused by narrowing or blockage of the blood vessels that carry blood from the heart to the lungs, increasing blood pressure within the lungs. PAH is a serious and progressive condition that can eventually lead to heart failure.

At Johnson & Johnson, we are focused on delivering new ways to tackle PAH, transforming the disease into a long-term manageable condition.

As with all medicines, Opsynvi may be associated with side effects. The most common side effects are headache and peripheral oedema (swelling caused by fluid buildup in the body). Please refer to the Opsynvi Consumer Medicine Information for further information on side effects, contraindications, precautions and warnings::https://innovativemedicine.jnj.com/australia/download/opsynvi-cmi.pdf

: The first new type of medicine for major depression to be funded by the government in three decades will soon be made...
30/04/2025

: The first new type of medicine for major depression to be funded by the government in three decades will soon be made available through the Pharmaceutical Benefits Scheme (PBS).

From tomorrow, SPRAVATO (esketamine), an antidepressant nasal spray, will be reimbursed for adults with treatment-resistant depression – major depressive disorder which has not responded adequately to at least two different antidepressants of adequate dose and duration to treat the current moderate to severe depressive episode. SPRAVATO is used in conjunction with a newly-initiated oral antidepressant.

We’d like to thank the many Australians who advocated for affordable access to SPRAVATO.

All medicines have side effects. When used with an oral antidepressant, the most common side effects of SPRAVATO include dissociation, dizziness and nausea. Please refer to the SPRAVATO Consumer Medicine Information for further information on side effects, contraindications, precautions and warnings:https://innovativemedicine.jnj.com/australia/download/spravato-cmi.pdf

21/01/2025

Around 1,100 Australians lose their lives to multiple myeloma every year.

Yet, Australians who are newly diagnosed with this type of cancer don’t have affordable access to a medicine that is funded in 38 countries overseas.

A government committee is now considering whether to fund this medicine as a first line of defence for around 1,500 Australian multiple myeloma patients who are ineligible for a stem-cell transplant.

Should Australia keep pace with the rest of the world? You can have your say!

Submit your comments before 29 January by selecting DARATUMUMAB - Darzalex® from the drop-down menu: https://bit.ly/3BtJ3tO



Please refer to Consumer Medicine Information for Darzalex at: https://bit.ly/4iRbr9O

16/01/2025

Did you know that Australia has one of the world’s highest death rates from multiple myeloma?

A government committee is considering whether to fund a new treatment option for Australians who are diagnosed with multiple myeloma and are ineligible for a stem-cell transplant. This medicine is widely available overseas.

You can help the committee understand the importance of this PBS funding decision.

Have your say before 29 January by selecting DARATUMUMAB - Darzalex® from the drop-down menu: https://bit.ly/3BtJ3tO



Please refer to Consumer Medicine Information for Darzalex at: https://bit.ly/4iRbr9O

15/01/2025

Do you know someone impacted by lung cancer?

More than 2,000 Aussies are diagnosed with EGFR-positive non-small cell lung cancer every year.

It is caused by changes in the EGFR gene.

A government committee is considering whether a new type of targeted medicine should be funded through the PBS for this deadly form of lung cancer.

You can help! Submit a comment before 29 January by selecting AMIVANTAMAB WITH LAZERTINIB - Rybrevant®Lazcluze® from the drop-down menu: https://bit.ly/4ftsUSR

15/01/2025

New treatment option for multiple myeloma – have your say.

A government committee is considering whether to make DARZALEX (daratumumab) affordable through the PBS for Australians with newly diagnosed multiple myeloma who are not eligible for a stem-cell transplant.

You can help the committee understand the importance of this PBS funding decision.

Have your say before 29 January by selecting DARATUMUMAB - Darzalex® from the drop-down menu: https://bit.ly/3BtJ3tO



Please refer to Consumer Medicine Information for Darzalex at: https://bit.ly/4iRbr9O

13/01/2025

Lung cancer can happen to anyone. It doesn’t discriminate.

EGFR-positive non-small cell lung cancer is caused by changes in the EGFR gene.

This form of lung cancer is more common in women, non-smokers and younger patients than other forms of lung cancer.

A government committee is considering whether a new type of targeted medicine should be available on the PBS for Australians with this form of lung cancer.

You can have your say. Submit your comments before 29 January by selecting AMIVANTAMAB WITH LAZERTINIB - Rybrevant®Lazcluze® from the drop-down menu: https://bit.ly/4ftsUSR

10/01/2025

38 countries fund a medicine for people who are newly diagnosed with multiple myeloma – Australia is not one of them.

In fact, there has been no new type of treatment for Australians newly diagnosed with multiple myeloma in over a decade.

A government committee is considering whether to make DARZALEX (daratumumab) affordable through the PBS for Australians with newly diagnosed multiple myeloma who are not eligible for a stem-cell transplant.

You can help these Australians access the latest medicine.

Have your say before 29 January by selecting DARATUMUMAB - Darzalex® from the drop-down menu: https://bit.ly/3BtJ3tO



Please refer to Consumer Medicine Information for Darzalex at: https://bit.ly/4iRbr9O

03/01/2025

Sadly, Australia lags many parts of the world in the treatment of multiple myeloma.

Each year, 1,500 Australians diagnosed with the blood and bone marrow cancer can’t receive a stem-cell transplant and instead require medication.

However, they do not yet have affordable access to the latest medicine, which is funded in 38 countries overseas.

A government committee is considering whether to fund this medicine for these Australians through the PBS and you can have your say!

Submit your comments before 29 January by selecting DARATUMUMAB - Darzalex® from the drop-down menu: https://bit.ly/3BtJ3tO

Please refer to Consumer Medicine Information for Darzalex at: https://bit.ly/4iRbr9O

29/12/2024

Lung cancer is Australia’s biggest cancer killer.

But not all lung cancers are the same. EGFR-positive non-small cell lung cancer is caused by changes in the EGFR gene.

Sadly, only 1-in-5 people with this type of lung cancer are still alive five years after diagnosis.

A government committee is considering whether a new type of targeted medicine should be available on the PBS for this form of lung cancer.

You can help give Australians living with EGFR-positive non-small cell lung cancer a and by showing your support for the funding of this medicine.

Have your say by selecting AMIVANTAMAB WITH LAZERTINIB - Rybrevant®Lazcluze® from the drop-down menu: https://bit.ly/4ftsUSR

Address

66 Waterloo Road
Macquarie Park, NSW
2113

Telephone

+61298153333

Website

Alerts

Be the first to know and let us send you an email when Johnson & Johnson ANZ posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Johnson & Johnson ANZ:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category